About: Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model
Creator	Li, Haiyan Cui, Cheng Song, Chunli Yao, Xueting Zhang, Miao Cai, Ting Shen, Ning Lin, Jing Qiao, Jie Zhang, Shun Q4, Q5 Hou, Zhe Tu, Siqi Xiang, Xiaoqiang En, Jie Liu, Dong-Yang Sia, Valerie
Source	Elsevier; Medline; PMC
abstract	Chloroquine (CQ) phosphate has been suggested to be clinically effective in the treatment of coronavirus disease 2019 (COVID-19). To develop a physiologically-based pharmacokinetic (PBPK) model for predicting tissue distribution of CQ and apply it to optimize dosage regimens, a PBPK model, with parameterization of drug distribution extrapolated from animal data, was developed to predict human tissue distribution of CQ. The physiological characteristics of time-dependent accumulation was mimicked through an active transport mechanism. Several dosing regimens were proposed based on PBPK simulation combined with known clinical exposure–response relationships. The model was finally validated by clinical data from Chinese patients with COVID-19. The novel PBPK model allows in-depth description of the pharmacokinetics of CQ in several key organs (lung, heart, liver, and kidney), and was applied to design dosing strategies in patients with acute COVID-19 (Day 1: 750 mg BID, Days 2–5: 500 mg BID, CQ phosphate), patients with moderate COVID-19 (Day 1: 750 mg and 500 mg, Days 2–3: 500 mg BID, Days 4–5250 mg BID, CQ phosphate), and other vulnerable populations (e.g., renal and hepatic impairment and elderly patients, Days 1–5: 250 mg BID, CQ phosphate). A PBPK model of CQ was successfully developed to optimize dosage regimens for patients with COVID-19.
has issue date	2020-04-20(xsd:dateTime)
bibo:doi	10.1016/j.apsb.2020.04.007
bibo:pmid	32834950
has license	no-cc
sha1sum (hex)	fb6a00358b7d8a197b422a60a06cdb2022e28f31
schema:url	https://doi.org/10.1016/j.apsb.2020.04.007
resource representing a document's title	Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model
has PubMed Central identifier	PMC7252145
has PubMed identifier	32834950
schema:publication	Acta Pharm Sin B
resource representing a document's body	covid:fb6a00358b7d8a197b422a60a06cdb2022e28f31#body_text
is schema:about of	named entity 'optimize' named entity 'parameterization' named entity 'dosage' named entity 'physiologically based pharmacokinetic' named entity 'developed' named entity 'phosphate' named entity 'distribution' named entity 'physiological' named entity 'PBPK' named entity 'model' named entity 'phosphate' named entity 'tissue distribution' named entity 'PBPK' named entity 'chloroquine phosphate' named entity 'COVID' named entity 'PBPK' named entity 'clinical setting' named entity 'safety profile' named entity 'pregnant women' named entity 'physiological' named entity 'liver' named entity 'PBPK' named entity 'clinical treatment' named entity 'C max' named entity 'PBPK' named entity 'PBPK' named entity 'area under curve' named entity 'plasma' named entity 'lung tissue' named entity 'glomerular filtration rate' named entity 'Informed Consent' named entity 'liver' named entity 'infection' named entity 'kidney' named entity 'plasma' named entity 'Calu-3' named entity 'liver' named entity 'concentration ratio' named entity 'Embase' named entity 'pregnant women' named entity 'liver' named entity 'ng/mL' named entity 'phosphate' named entity 'liver' named entity 'PBPK' named entity 'hepatic' named entity 'receptor' named entity 'COVID' named entity 'chloroquine phosphate' named entity 'PBPK' named entity 'lung tissue' named entity 'QSAR model' named entity 'plasma' named entity 'plasma' named entity 'rat' named entity 'HLM' named entity 'plasma' named entity 'lung' named entity 'glomerular filtration rate' named entity 'endosomal' named entity 'virus' named entity 'chloroquine' named entity 'phosphate' named entity 'plasma' named entity 'plasma'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software